Cover Image

Anti‐mitotic agent SB‐216 overcomes taxane resistance in castration‐resistant prostate cancer and exhibits anti‐tumour efficacy in pancreatic cancer

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Rui Wang, Chun Cai, Shanshan Deng, Yang Xie, Satyanarayana Pochampally, David J. Hamilton, Bernd Meibohm, Evan S. Glazer, Duane D. Miller, Wei Li
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	British Journal of Pharmacology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)
by: Celestia S. Higano, et al.
Published: (2024)

Current state of theranostics in metastatic castrate‐resistant prostate cancer
by: Udit Nindra, et al.
Published: (2024)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer
by: Nicolas Gordon, et al.
Published: (2026)

Editorial Comment to Survival beyond cabazitaxel for metastatic castration‐resistant prostate cancer
by: Yoshiyuki Yamamoto, et al.
Published: (2024)

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients
by: Tokiyoshi Tanegashima, et al.
Published: (2024)

Clinical and pathological prognostic factors for prostate cancer progression to a castration resistant disease
by: Ahmed Abdul, Hussein Attyia, et al.
Published: (2024)

Comparative analysis of gut microbiota in hormone‐sensitive and castration‐resistant prostate cancer in Japanese men
by: Saizo Fujimoto, et al.
Published: (2024)

Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis
by: Joana Simões
Published: (2018)

Percentage of free to total PSA as a biomarker of survival in metastatic castration‐resistant prostate cancer
by: Andrew W. Silagy, et al.
Published: (2025)

A practical guide for the use of apalutamide for non‐metastatic castration‐resistant prostate cancer in Australia
by: Gavin Marx, et al.
Published: (2024)

Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
by: Thomas Büttner, et al.
Published: (2024)

FAM107A loss facilitates TTK‐OPTN‐mediated mitophagy to drive docetaxel resistance in castration‐resistant prostate cancer
by: Yishan Zhang, et al.
Published: (2026)

Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”
by: Tokiyoshi Tanegashima, et al.
Published: (2024)

Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer
by: Megan E. V. Caram, et al.
Published: (2024)

Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center
by: Thomas Büttner, et al.
Published: (2024)

Prostate cancer cancer‐associated fibroblasts with stable markers post‐androgen deprivation therapy associated with tumor progression and castration resistant prostate cancer
by: Shen Pan, et al.
Published: (2024)

Selective killing of castration‐resistant prostate cancer cells by formycin A via the ATF4–CHOP axis
by: Tomoki Takei, et al.
Published: (2024)

Histone demethylase LSD1 promotes castration‐resistant prostate cancer by causing widespread gene expression derangements
by: Haiying Li, et al.
Published: (2025)

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
by: Ondřej Fiala, et al.
Published: (2024)

Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer
by: Chen Liang, et al.
Published: (2025)

Combined immunotherapy employing Wilms' tumor 1 peptide‐pulsed dendritic cells and hormone or chemotherapeutic agents in patients with metastatic castration resistant prostate cancer
by: Masahiro Ogasawara, et al.
Published: (2025)

[225Ac]Ac‐PSMA for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis
by: Maria Luisa Garo, et al.
Published: (2024)

PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis
by: Michela Roberto, et al.
Published: (2025)

Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa
by: Nobumichi Tanaka, et al.
Published: (2024)

A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer
by: Daniel Boiarsky, et al.
Published: (2024)

Clinical impact of real‐time androgen receptor alteration monitoring on metastatic castration‐resistant prostate cancer treatment in real‐world settings
by: Regina Stitz, et al.
Published: (2025)

CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration‐resistant prostate cancer
by: Yayi Dwina, et al.
Published: (2024)

Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer
by: Haozhe Zhang, et al.
Published: (2024)

Framework to calculate 225 Ac, 177 Lu, and 161 Tb radiation dose and biological effect in metastatic castration‐resistant prostate cancer treatment
by: Shahin Ghaseminejad, et al.
Published: (2025)

Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer
by: Kate L. Mahon, et al.
Published: (2024)

STK25 inhibits cancer‐associated fibroblast activation to overcome cetuximab resistance in colorectal cancer
by: Yifan Hou, et al.
Published: (2026)

A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin‐induced apoptosis in castration‐resistant prostate cancer
by: Pei‐Chen Ye, et al.
Published: (2024)

Functional combination of resveratrol and tamoxifen to overcome tamoxifen‐resistance in breast cancer cells
by: Aliaa M. Radwan, et al.
Published: (2024)

Correlation analyses of radiographic progression‐free survival with clinical and health‐related quality of life outcomes in metastatic castration‐resistant prostate cancer: Analysis of the phase 3 VISION trial
by: Michael J. Morris, et al.
Published: (2024)

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients
by: Richell Booijink, et al.
Published: (2024)

Castration-resistant prostate cancer: Why should urologists care?
by: Judd W. Moul
Published: (2016)

Androgen‐repressed lncRNA LINC01126 drives castration‐resistant prostate cancer by regulating the switch between O‐GlcNAcylation and phosphorylation of androgen receptor
by: Yi Cai, et al.
Published: (2024)

Reprogramming innate immunity to overcome endocrine resistance in estrogen receptor‐positive breast cancer
by: Siti Nur Hasyila Muhammad, et al.
Published: (2026)

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance
by: Junyan Li, et al.
Published: (2026)

Combination therapy enhances efficacy and overcomes toxicity of metal‐based anti‐diabetic agent
by: Bing Shang, et al.
Published: (2024)